Sodium Oxybate in Spasmodic Dysphonia and Voice Tremor

PHASE2/PHASE3CompletedINTERVENTIONAL

Enrollment

117

Participants

Timeline

Start Date

January 22, 2018

Primary Completion Date

December 29, 2021

Study Completion Date

October 11, 2024

Conditions

Spasmodic DysphoniaVoice Tremor

Interventions

DRUG

Sodium Oxybate

Alcohol challenge test and oral administration of a single dose of sodium oxybate and the matching placebo.

Trial Locations (1)

Massachusetts Eye and Ear, Boston

All Listed Sponsors

collaborator

National Institute on Deafness and Other Communication Disorders (NIDCD)

NIH

lead

Kristina Simonyan

OTHER

NCT03292458 - Sodium Oxybate in Spasmodic Dysphonia and Voice Tremor | Biotech Hunter | Biotech Hunter